biontech mrna - Search News

News

BioNTech to buy German rival CureVac for $1.25B

Reuters on MSN · 3d

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

Fierce Biotech · 4d

BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.

MedCity News · 3d

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.

GlobalData on MSN3d

BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results